Lung cancer is a leading cause of death in the United States and
around the world. A frequent and serious consequence of the disease is
metastasis to the brain.
New therapies mean survival from lung cancer
continues to improve and patients are at increased risk of developing
later complications of the disease, such as brain metastases.
Understanding prognosis for lung cancer is important, both for designing
individualized care and future clinical trials.
‘The original Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) has been updated with new genetic and molecular data to create a new index called the Lung-moIGPA, which can be accessed electronically.’
A new article published online by JAMA Oncology
updates a tool to estimate survival in patients with lung cancer and brain metastases.
In their article, Paul W. Sperduto of Minneapolis
Radiation Oncology and the University of Minnesota, Minneapolis, and
coauthors update the original Diagnosis-Specific Graded Prognostic
Assessment (DS-GPA) with new genetic and molecular data to create a new
index called the Lung-moIGPA, which can be accessed electronically.
The updated Lung-moIGPA was designed by analyzing data from 2,186
patients in a multi-institution database from 2006 through 2014 with
non-small cell lung cancer and newly diagnosed brain metastases. Two new
prognostic factors were used in the new Lung-moIGPA: EGFR and ALK gene
mutations. The authors reported overall median survival in the patient
group was 12 months.
Study limitations include its design, which cannot establish causality.
"The updated Lung-moIGPA incorporating gene alteration data into the
DS-GPA is a user-friendly tool that may facilitate clinical
decision-making and appropriate stratification of future clinical
trials," the study concludes.